Iron Bioavailability in Dana Shakti pearl millet

MRC Unit The Gambia at LSHTM0 个研究点目标入组 60 人开始时间: 2021年4月23日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Women between the ages of 18-50
•Not pregnant
•Willingness to reside in the study site area for the length of the study and are able and willing to adhere to all protocol
•Healthy with no current illness and no chronic health problems, asked verbally by field worker
•Signed or fingerprinted informed consent obtained

•Acute illness (once the acute illness is resolved, if appropriate, as per investigator assessment, the participant may be re-evaluated for eligibility)
•Fever (for eligibility purpose defined as a body temperature greater than 37.5°C) within 3days prior to study initiation (once fever/acute illness is resolved, if appropriate, as per investigator assessment. The participant may be re-evaluated for eligibility)
•Administration of any investigational drug within 30 days prior to study initiation or planned administration during the study period
•Unwilling to avoid the ingestiob of supplements or herbal/other traditional medications during the study period
•Any history of evidence for chronic clinically significant (as per investigator assessment) disorder or disease (included, but not limited to, immunodeficiency, autoimmunity, congenital abnormality, bleeding disorder, and pulmonary, cardiovascular, metabolic, neurologic, renal, or hepatic disease
•Any history of human immunodeficiency virus, chronic hepatitis B or chronichepatitis C infections
•History of meningitis, seizures, Guillain-Barre syndrome, or other neurological disorders
•Any condition that in the opinion of the investigator might compromise the safety or well-being of the participant or compromise adherence to protocol procedures

发起方

MRC Unit The Gambia at LSHTM